Skip to content

PRF in Management of Chronic Multiple Oral Ulcers

Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03878771
Enrollment
804
Registered
2019-03-18
Start date
2019-03-13
Completion date
2019-04-15
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Ulcer Due to Benign Mucous Membrane Pemphioid, Oral Ulcer Due to Pemphius Vularis, Oral Ulcer Due to Steven Johnson's Syndrome

Keywords

Platelet rich fibrin, Oral Ulcer, Pain, Mucositis

Brief summary

PRF in orabase will be applied as a pack material on chronic oral ulcers of chronic multiple oral lesions compared to conventional topical steroid therapy with clobetasol propionate 0.05% in orabase. The outcomes measured are Pain alleviation as Primary outcome and Clinical improvement in terms of Ulcer size, Number and Mucositis score as Secondary outcomes. Time frame for outcomes assessment will be Daily for 7 Days regarding pain score and weekly for 2 weeks regarding clinical improvement.

Detailed description

The management of oral ulcers and mucositis specially the resistant types such as oral ulcers due to auto-immune diseases is a major concern by the dentists through all the world. Topical corticosteroids, analgesics, Laser bio modulation all have been proposed as treatments with limited efficacy in many cases. There are few number of clinical trials on Plasma preparation in management of oral mucositis and oral ulcers. Platelet rich fibrin (PRF) is one of the platelet concentrates. The preparation protocol of PRF is simple and easy, could be prepared autologous and immediately placed on the oral ulcers and mucositis. Subjects and Methods: A non Randomized clinical trial will be conducted. Ten patients with different resistant oral ulcers and mucositis were enrolled. all with grade 4 WHO mucositis score. The initial numerical ratting score of pain is 10. For all patients 20 ml blood sample will obtained in plain blood vacutainer, centrifuged for 15 minutes on 3000 rpm. The resultant gel, obtained and squeezed to prepare a membrane, the membrane will be mixed with orabase and placed over the oral ulcers and mucositis over a piece of gauze. The patients will be instructed not to eat or drink for 2 hours after application. The remaining serum after squeezing was mixed with equal amount of orabase and used topically on the oral mucositis and ulcers. Clobetasol Propionate 0.05% in orabase will be applied to 10 control patients 3 times per day for one week. The steps will be repeated after one week if the patients' symptomatic scores for WHO and numerical rating score were not zero.

Interventions

BIOLOGICALPlatelet rich fibrin gel in Orabase

applied on oral mucositis and /or ulcer 3 times per day

DRUGDermovate cream in Orabase

applied on oral mucositis and /or ulcer 3 times per day

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients with chronic multiple oral lesions due to benign mucous membrane Pemphigoid, Pemphigus vulgaris, ans Steven Johnson's Syndrome

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with Oral ulcers due to Benin mucous membrane pemphioid, Pemphius vulgaris and Steven Johnson's Syndrome with mucositis score 4 and pain score 10

Exclusion criteria

* patients with any systemic other systemic condition

Design outcomes

Primary

MeasureTime frameDescription
Pain score1 weekNumerical Rating score of Pain, graded from 0 to 10, were 0 is no pain at all and 10 represent severe pain, obtaining lower values reflects improvement

Secondary

MeasureTime frameDescription
Mucositis2 weeksWHO mucositis score, graded from 0 to 4 were 0 no mucositis and 4 severe mucositis, obtaining lower values reflects improvement
ulcer size2 weeksMeasurement in cm for the largest ulcer, expressed as maximum height x maximum width reflecting the average size, decrease in size is improvement
ulcer number2 weeksnumber counted for each patient, decrease in number reflects improvement

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026